X-Linked Retinitis Pigmentosa (XLRP)
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Gene Therapy
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Beacon TherapeuticsMA - Cambridge
1 program1
Adeno-associated virus vector expressing a human RPGR genePhase 2Gene Therapy1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
2030
Beacon TherapeuticsAdeno-associated virus vector expressing a human RPGR gene
Frontera TherapeuticsFT-002
Clinical Trials (2)
Total enrollment: 42 patients across 2 trials
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Start: Sep 2025Est. completion: Dec 203010 patients
Phase 2Recruiting
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
Start: Apr 2024Est. completion: Feb 202632 patients
Phase 1/2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 42 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.